|
大家看一下算法有没有问题. 看上去要发财了.
网上根据XNPT 批后从GSK拿到的第一笔钱算出的可能股价:
====================
Potential XNPT PPS we should get if we get approved:
It currently has 30 mils shares outstanding. So book value per share earning
is: 5/0.3 = $16.6
EPS: 166 * 10 = 166.
So the potential PPS = current PPS + 166 = $184.
If we exclude sales milestones:
book value per share earning is: 2.5/0.3 = $8
EPS: 8 * 10 = 80
potential PPS = current PPS + 80 = $98
===============================
如果只用XNPT的BOOK VALUE 来算, 也应该到$26.如果买家大量增加,有可能到
以前的最高点出$66. 这可是XNPT的第一个重要药物.
从各种渠道看到的数据和NEWS, 都很POSITIVE. 我的结论是肯定会批. FDA甚至不需要
咨询小组的建议来审核XP13512的申请。它的PARTNER是GSK和ASTELLAS. |
|